Quarterly Activities & Appendix 4C September 2024

● Biome records $122k of EBITDA for Q1 (Adjusted for share based payments)
○ Third consecutive quarter of positive EBITDA
● Record cash receipts of $3.89m in Q1, up 84% vs PCP
● Biome reports record quarterly sales revenue $4.25m, up 12% vs Q4 FY24
● Biome maintains gross margin above 60% for Q1
● Same-store pharmacy sales for Q1 up 68% vs PCP
● Clinically proven cholesterol lowering product, Biome Cholesterol launched
● Test market in Canada commenced and strategic distribution deal signed
● As at September 30th, the company has a cash balance of $2.67m